Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
BerGenBio ASA
ABM Therapeutics Corporation
ABM Therapeutics Corporation
Sumitomo Pharma America, Inc.
Karyopharm Therapeutics Inc
Quadriga Biosciences, Inc.
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Celgene
Tocagen Inc.
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Novartis
Duke University
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center